Proposed US COINS Act rules for China biotech deals
Why transaction structure matters.
The US Department of the Treasury’s proposed biotechnology restrictions would generally leave standalone drug licenses outside the US outbound investment regime. Related financing, shared development, and NewCo arrangements may nevertheless be prohibited, making structure critical to China-origin deals.
Treasury issued the proposal (91 Fed. Reg. 67396) on October 22, 2026;